On July 1, 2022, Senzime completed the acquisition of 100 percent of the shares in Respiratory Motion, as was made public on June 1, 2022. Senzime's board of directors has resolved to issue 2,127,537 new shares to the sellers of Respiratory Motion at a subscription price of SEK18.59 per share. Respiratory Motion is a Boston-based medtech company that develops and commercializes systems for the monitoring of respiratory function and other vital signs. The company's solution—ExSpiron—is the only non-invasive system on the market that monitors patients' breathing volume and real-time breathing frequency. The system is CE and FDA approved and validated on over 6,000 patients.

The Wilson Sonsini Goodrich & Rosati team that represented Respiratory Motion in the transaction included Elton Satusky, Brian Appel, Roy Argand, Ryan Isola, Lenka Schvaigerova, and Michael Klippert.

For more information, please see Senzime's press release.